← Back to Tessera Defense and Homeland Security Stock
Tessera Defense and Homeland Security (HLSQ) News
https://www.investing.com/news/company-news/biomx-shareholders-approve-preferred-stock-conversion-93CH-3513319
GAITHERSBURG, Md., July 10, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company's stockholders have voted to approve a proposal to convert BiomX's outstanding Series X Non-Voting Convertible Preferred Stock (“Series X Preferred Stock”) into shares of BiomX's common stock. The result of the vote was previously disclosed in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on July 9, 2024.
An update from BiomX (PHGE) is now available. At the Annual Meeting, shareholders of the Company decisively voted to increase the authorized shares…
BiomX (PHGE) has issued an announcement. BiomX, Inc. has been notified by NYSE American that it’s not meeting the required listing standards due to…
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification (“the Notice”) from the NYSE American LLC (“NYSE American”), dated May 23, 2024, stating that the Company is no longer in compliance with continued listing standards, as set forth in Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”).
GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the Company will present at two upcoming conferences data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections. The findings will be presented in an oral presentation and an ePoster at the 47th European Cystic Fibrosis Conference, which is taking place June 5-8, 2024, in Glasgow, United Kingdom, and in a Rapid Fire oral presentation and a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-17, 2024, in Atlanta, Georgia.
https://www.investing.com/news/company-news/biomx-shares-target-cut-amid-q1-results-and-merger-93CH-3451794
BiomX Inc. (NYSE:NYSE:PHGE) Q1 2024 Earnings Conference Call May 21, 2024 8:00 AM ETCompany ParticipantsJonathan Solomon - Chief Executive OfficerAvi Gabay…
BiomX Inc. (NYSE:PHGE ) Q1 2024 Earnings Conference Call May 21, 2024 8:00 AM ET Company Participants Jonathan Solomon - Chief Executive Officer Avi Gabay - Chief Financial Officer Conference Call Participants Joe Pantginis - HC Wainwright Yale Jen - Laidlaw & Co. Sohanna - Ladenburg Thalmann Operator Hello and welcome to the BiomX first quarter 2024 financial results. If anyone should require Operator assistance, please press star, zero on your telephone keypad.
Following merger with Adaptive Phage Therapeutics in March, combined company reports funding sufficient to support important data readouts for lead clinical programs in 2025